Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21

Articles

Pages

26651 items
1:22 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Lilly planning Phase III trials for Olumiant in lupus

Eli Lilly and Co. (NYSE:LLY) said it plans to start this year Phase III testing of Olumiant baricitinib to treat systemic lupus erythematosus (SLE) after reporting that the higher dose of the drug met the...
1:22 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Elios' dendritic cell vaccine leads to no significant difference in recurrence in Phase IIb for melanoma

Elios Therapeutics LLC (Austin, Texas) reported interim data from 120 patients with stage III or IV resected melanoma in a Phase IIb trial showing that the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine led to...
1:21 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Vical discontinuing HSV-2 program after Phase II miss

Vical Inc. (NASDAQ:VICL) said it will discontinue development of VCL-HB01 after the HSV-2 vaccine missed the primary endpoint in a Phase II trial. VCL-HB01 is a plasmid DNA vaccine that encodes the HSV-2 glycoprotein D and...
1:14 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Eisai, Purdue's insomnia candidate does not impair driving in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 106 showing that insomnia candidate lemborexant (E2006) given each night at bedtime met the primary endpoint of...
12:32 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

vTv to propose path forward for AD candidate despite Phase III miss

vTv Therapeutics Inc. (NASDAQ:VTVT) said azeliragon (TTP488) missed the co-primary endpoints compared with placebo in Part B of the Phase III STEADFAST trials to treat mild Alzheimer’s disease. Despite the miss, the company said it...
12:31 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

MEI reports 90% ORR in Phase Ib of ME-401 in hematologic malignancies

MEI Pharma Inc. (NASDAQ:MEIP) reported updated data from 30 evaluable patients with relapsed or refractory follicular lymphoma or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in a Phase Ib trial showing that once-daily ME-401 led...
12:30 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

MEI's ME-344 inhibits tumor cell proliferation in breast cancer trial

MEI Pharma Inc. (NASDAQ:MEIP) said ME-344 plus Avastin bevacizumab led to greater inhibition of tumor cell proliferation compared with placebo plus Avastin as measured by the mean reduction in antigen KI-67 (MKI67; Ki-67) expression in...
12:29 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

ViiV's two-drug HIV regimen meets in Phase III for HIV

ViiV Healthcare Ltd. (Brentford, U.K.) said its two-drug regimen of dolutegravir and lamivudine met the primary endpoint in a pair of Phase III trials to treat HIV-1 infection in treatment-naïve patients with baseline viral loads...
12:28 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Eureka reports Phase I response data for anti-CD19 T cell therapy in lymphoma

Eureka Therapeutics Inc. (Emeryville, Calif.) reported preliminary data from 17 evaluable patients with CD19-positive, relapsed and refractory B cell lymphoma in a Phase I trial showing that IV ET190L1-ARTEMIS led to seven complete metabolic responses...
12:20 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Imbruvica, Venclexta combo leads to responses with no detectable MRD in Phase II for CLL

AbbVie Inc. (NYSE:ABBV) said 23 of the first 30 evaluable patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the Phase II CAPTIVATE (PCYC-1142) trial achieved a response with no...

Pages